Recombinant hirudin in clinical practice - Focus on lepirudin

被引：118

作者：

Greinacher, A ^{[1
]}

Lubenow, N ^{[1
]}

机构：

[1] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, Klinikum Sauerbruchstr, D-17489 Greifswald, Germany

来源：

CIRCULATION | 2001年 / 103卷 / 10期

关键词：

recombinant hirudin; platelets; thrombosis; cardiovascular diseases; heparin;

D O I：

10.1161/01.CIR.103.10.1479

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical applications for recombinant hirudins have been investigated for the past 10 years. The first indication for which a hirudin-lepirudin-has been approved is treatment of heparin-induced thrombocytopenia (HIT). Also, the recently completed trials for use of lepirudin in unstable angina indicate a potentially new indication. This review describes pharmacology and clinical applications of lepirudin with an emphasis on HIT and unstable angina. An overview of usage of lepirudin in acute coronary syndromes is given, as well as a summary of rare indications for lepirudin, such as extracorporeal circulation, for which comprehensive data are lacking.

引用

页码：1479 / 1484

页数：6

共 57 条

[51] SERA FROM PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA GENERATE PLATELET-DERIVED MICROPARTICLES WITH PROCOAGULANT ACTIVITY - AN EXPLANATION FOR THE THROMBOTIC COMPLICATIONS OF HEPARIN-INDUCED THROMBOCYTOPENIA [J].